Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
LXRX Stock Chart & Stats
$1.37
-$0.12(-12.49%)
At close: 4:00 PM EST
$1.37
-$0.12(-12.49%)
Day’s Range― - ―
52-Week Range$0.28 - $1.66
Previous CloseN/A
Volume2.02M
Average Volume (3M)1.52M
Market Cap
$497.86M
Enterprise Value$506.35M
Total Cash (Recent Filing)$115.95M
Total Debt (Recent Filing)$58.15M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Mar 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding363,398,680
10 Day Avg. Volume1,411,003
30 Day Avg. Volume1,523,218
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.62
Price to Sales (P/S)7.60
P/FCF Ratio-1.31
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue7.15
Enterprise Value/Gross Profit11.33
Enterprise Value/Ebitda-10.48
Forecast
1Y Price Target
$4.03Price Target Upside194.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$14.96M
Bulls Say, Bears Say
Bulls Say
Phase 3 Clinical Trial ProgressProgress and enrollment in the Phase 3 SONATA-HCM program could establish sotagliflozin as a differentiated treatment for both obstructive and non-obstructive hypertrophic cardiomyopathy by demonstrating structural, functional, and safety benefits.
Pipeline Breadth And Financial RunwayA diversified late-stage pipeline spanning diabetic neuropathic pain, hypertrophic cardiomyopathy, and type 1 diabetes, together with a cash runway extending into 2026, supports multiple paths to value and continuation of pivotal programs.
Regulatory Opportunity For T1DA potential NDA resubmission for Zynquista as an add-on to insulin, supported by additional safety data, could materially increase visibility and create a new commercial opportunity in type 1 diabetes.
Bears Say
Partnership Dependence RiskDependence on securing a partner for pilavapadin's Phase 3 development and commercialization creates downside risk if a suitable collaborator is not found or partnership terms are unfavorable.
Regulatory And Execution RiskRegulatory resubmission requirements and pivotal trial outcomes carry higher-than-normal execution risk, so setbacks in approvals or trial results could significantly pressure the stock.
Safety Concerns For Lead ProgramFDA concerns about diabetic ketoacidosis rates with Zynquista represent a material safety hurdle that could delay approval, restrict labeling, or limit commercial uptake.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.28 and its highest was $1.66 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $497.86M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Mar 18, 2026 which is in 59 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.066 by $0.026.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.07.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 363,398,680 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.066. Following the earnings report the stock price went up 3.623%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.03 (194.16% Upside)
$4.03 (194.16% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 229.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.14%
12-Months-Change
Fundamentals
Return on Equity
-45.92%
Trailing 12-Months
Asset Growth
-35.87%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX Company Deck
LXRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive progress in revenues, R&D advancements, and strategic partnerships, while also highlighting challenges such as decreased cash reserves and the need for FDA feedback for key products. Overall, the positive aspects of the company's progress and strategic focus on future opportunities suggest a cautiously optimistic outlook.View all LXRX earnings summariesLXRX Stock 12 Month Forecast
Average Price Target
$4.03
▲(194.16% Upside)
Technical Analysis
Ownership Overview
13.05% Insiders
8.74% Mutual Funds
0.26% Other Institutional Investors
75.25% Public Companies and
Individual Investors